New GP contract incentivises lower carbon inhalers
The new GP contract published last week includes a new incentive to encourage lower carbon inhalers.
See pg 60: Reducing the carbon impact of inhalers
37. The NHS has committed to reducing the carbon impact of inhalers used in the treatment of respiratory conditions by 50%. These impacts are described in the 2019 BTS/SIGN Asthma guidelines and by NICE in its 2019 Shared Decision Aid on Asthma. All inhaler prescriptions, Structured Medication Reviews or planned Asthma Reviews taking place in primary care should consider moving or facilitating patients to lower carbon options where it is clinically appropriate to do so.
This will be backed by funding through the £6.25m Investment and Impact Fund.
See pg 49: TABLE 6: 2020/21 IIF INDICATORS AND THRESHOLDS- Metered Dose Inhaler prescriptions as a percentage of all inhaler prescriptions (excluding salbutamol
- The scope is non-salbutamol inhalers (of which 51% are MDI currently)
- The target is to shift from 51% to 45% MDI in 20/21- not specifying alternatives
- The approach is expected to form part of informed shared decision making at point of prescription and review.
- This approach should save over 20,000 tonnes of CO2 per annum by the end of 20/21
The https://openprescribing.net/measure/environmental_inhalers/ dashboard provides a picture of the current levels of MDI prescribing in this scope.